Macrohemodynamic Impact of Fluid Removal With Net Ultrafiltration in Patients With Continuous Renal Replacement Therapy
Launched by HOSPICES CIVILS DE LYON · May 21, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute kidney injury treated by continuous renal replacement therapy in ICU less than 7 days,
- • At least 1 organ failure during ICU in addition to AKI (mechanical ventilation or vasopressors administration\>12 hours),
- • Cumulative UF net less than 1000ml before inclusion,
- • Norepinephrine \< 0,5 µg/kg/min,
- • Absence of hypoperfusion signs,
- • Fluid overload defined as follows: fluid overload \> 5% of base weight (based on cumulative fluid balance or a weight gain) and/or peripheral edema (AKIKI edema scale \> 2).
- Exclusion Criteria:
- • Chronic renal failure hemodialyzed before admission to the ICU,
- • Mechanical circulatory support (ECMO, LVAD),
- • Pregnant, child -bearing age or lactating women,
- • Stroke less than 30 days,
- • Intestinal ischemia less than 7 days documented non-operated,
- • Interventional study participation or exclusion period on going,
- • Guardianship, curatorship or safeguard of justice,
- • Absence of signature of free and informed consent by the patient and/or relative,
- • Patients not affiliated to a social security scheme or beneficiaries of a similar scheme
- • Absence of transpulmonary thermodilution monitoring
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bron, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0